{
 "ticker": "GNOM",
 "name": "Global X Genomics & Biotechnology ETF",
 "issuer": "Global X",
 "desk": "themes",
 "url": "https://etfiq.com/funds/gnom",
 "html": "https://etfiq.com/funds/gnom",
 "markdown": "https://etfiq.com/funds/gnom.md",
 "as_of": "2026-09-11",
 "verdict": "GNOM holds 50 stocks, and 78% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "21.5%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "GNOM, already in the S&P 500: 21.5%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "97.6%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "GNOM, active share vs the S&P 500: 97.6%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "50.3%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "GNOM, top ten holdings: 50.3%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+69.7%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "GNOM, total return, 1 year: +69.7%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$94m",
   "source": "the issuer own daily fund list, as of Sep 11, 2026",
   "as_of": "2026-09-11",
   "sentence": "GNOM, net assets: $94m (the issuer own daily fund list, as of Sep 11, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.50%",
   "source": "485BPOS XBRL, Mar 27, 2026",
   "as_of": "2026-09-11",
   "sentence": "GNOM, expense ratio: 0.50% (485BPOS XBRL, Mar 27, 2026)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Biotech and genomics",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Apr 10, 2019",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "21.5%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "97.6%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "5.3%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "98.8%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "50.3%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "50",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Sep 11, 2026",
   "source": "the issuer\u2019s daily file"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "MODERNA INC 8.0%, 10X GENOMICS INC-CLASS A 6.2%, TWIST BIOSCIENCE CORP 6.0%, GUARDANT HEALTH INC 5.4%, NATERA INC 4.9%, ILLUMINA INC 4.9%, BIO-TECHNE CORP 3.8%, GENSCRIPT BIOTECH CORP 3.8%, BIOMARIN PHARMACEUTICAL INC 3.7%, VERTEX PHARMACEUTICALS INC 3.6%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$94m",
   "source": "the issuer own daily fund list, as of Sep 11, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u221243.4%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.50%",
   "source": "485BPOS XBRL, Mar 27, 2026"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.51%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "ARKG 40%, WDNA 35%, PBE 29%, HELX 29%, IDNA 26%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+27.2%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+23.9 pts",
   "Gap to Nasdaq-100": "+28.0 pts"
  },
  {
   "window": "6 months",
   "Total return": "+44.0%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+28.0 pts",
   "Gap to Nasdaq-100": "+23.3 pts"
  },
  {
   "window": "1 year",
   "Total return": "+69.7%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+52.2 pts",
   "Gap to Nasdaq-100": "+46.7 pts"
  },
  {
   "window": "3 years",
   "Total return": "+43.7%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u221234.2 pts",
   "Gap to Nasdaq-100": "\u221251.4 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+2.9%",
   "S&P 500": "+195.2%",
   "Gap to S&P 500": "\u2212192.3 pts",
   "Gap to Nasdaq-100": "\u2212300.6 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of GNOM is in S&P 500 companies?",
   "a": "By its holdings published by its issuer for Sep 11, 2026, 22% of GNOM by weight is stocks the S&P 500 already holds. Its active share against the index is 98%, so that share is the part doing something different."
  },
  {
   "q": "What does GNOM hold?",
   "a": "50 positions as published by its issuer for Sep 11, 2026, with the top ten at 50% of the fund. The largest are MODERNA INC at 8.0%, 10X GENOMICS INC-CLASS A at 6.2%, TWIST BIOSCIENCE CORP at 6.0%."
  },
  {
   "q": "Has GNOM beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 GNOM returned +69.7% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 52.2 points."
  },
  {
   "q": "What does GNOM cost?",
   "a": "The prospectus expense ratio is 0.50% a year. Because 98% of the fund differs from the S&P 500, the fee on that differing part works out at 0.51%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}